bisacodyl rectal (OTC)

Brand and Other Names:Fleet Bisacodyl Enema, Fleet Bisacodyl Suppository
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

enema

  • 10mg/30mL

suppository

  • 10mg

Constipation

Enema: Contents of 1 bottle (ie, 37 mL) rectally as a single dose

Suppository: Remove outer wrap and insert 1 suppository into rectum

Enema Administration

Patient should lie on left side with right knee bent

Gently insert enema tip into rectum using slight side-to-side movement; point enema tip toward navel (ease insertion by having patient bear down, as if having a bowel movement, to relax anal muscles)

Do not force enema tip into rectum

Squeeze bottle to deliver appropriate dose

Remove enema tip from rectum

Retain enema in accordance with doctor's instructions

Dosage Forms & Strengths

enema

  • 10mg/30mL

suppository

  • 10mg

Constipation

Enema

  • >12 years: As adults; contents of 1 bottle (ie, 37 mL) rectally as a single dose

Suppository

  • 6-12 years: Remove outer wrap and insert one-half suppository into rectum
  • >12 years: As adults; remove outer wrap and insert 1 suppository into rectum
Next:

Interactions

Interaction Checker

and bisacodyl rectal

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (2)

              • sodium sulfate/?magnesium sulfate/potassium chloride

                sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of bisacodyl rectal by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration of stimulant laxatives and sodium sulfate/magnesium sulfate/potassium chloride may increase the risk of mucosal ulceration or ischemic colitis.

              • sodium sulfate/potassium sulfate/magnesium sulfate

                sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of bisacodyl rectal by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration of stimulant laxatives and sodium sulfate/magnesium sulfate/potassium chloride may increase the risk of mucosal ulceration or ischemic colitis.

              Monitor Closely (1)

              • deflazacort

                bisacodyl rectal and deflazacort both decrease serum potassium. Use Caution/Monitor.

              Minor (2)

              • potassium acid phosphate

                bisacodyl rectal decreases levels of potassium acid phosphate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

              • potassium chloride

                bisacodyl rectal decreases levels of potassium chloride by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

              Previous
              Next:

              Adverse Effects

              Frequency Not Defined

              Abdominal cramping

              Excessive diarrhea

              Electrolyte and fluid imbalance

              Rectal burning

              Vertigo

              Vomiting

              Previous
              Next:

              Warnings

              Contraindications

              Hypersensitivity

              Obstruction

              Severe impaction

              Symptoms of appendicitis or acute surgical abdomen

              Vomiting

              Rectal bleeding

              Gastroenteritis

              Cautions

              Excessive use may cause electrolyte imbalance, steatorrhea, osteomalacia, diarrhea, & cathartic colon

              Previous
              Next:

              Pregnancy & Lactation

              Pregnancy category: N/A

              Lactation: Excretion in milk unknown

              Pregnant or breastfeeding patients should seek advice of health professional before using OTC drugs

              Pregnancy Categories

              A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

              B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

              C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

              D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

              X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

              NA: Information not available.

              Previous
              Next:

              Pharmacology

              Mechanism of Action

              May irritate the colonic intramural plexus of the intestine; alters water and electrolyte secretion, which in turn produces net intestinal fluid accumulation and laxation

              Pharmacokinetics

              Onset of action: 15-60 min

              Half-life: 8 hr (BHPM metabolite)

              Metabolism: Metabolized to BHPM in the colon

              Excretion: Urine (BHPM) and bile

              Previous
              Next:

              Images

              No images available for this drug.
              Previous
              Next:

              Patient Handout

              A Patient Handout is not currently available for this monograph.
              Previous
              Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.